MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
Read moreMEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
Read moreMEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
Read moreOncology Focused, Patient Centric
We are committed to the development of novel and differentiated cancer therapies intended to overcome known drug resistance mechanisms in combination with standard-of-care therapies to provide improved outcomes to patients.